Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.
BMI
albumin
immunotherapy
prognosis
weight
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
04
2019
accepted:
08
08
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
1
10
2019
Statut:
epublish
Résumé
Weight loss is a well-recognized prognostic parameter for survival of lung cancer patients. Computerized-tomography (CT)-based analysis of body composition and blood-based metabolic evaluation are promising prognostic tools. We aimed to assess the correlation between albumin, body mass index (BMI), skeletal muscle mass index (SMI), fat-free mass index (FFMI), fat mass index (FMI) and weight change, as well as their correlation with survival of lung cancer patients on nivolumab treatment. Data were retrospectively collected. Weight was measured at a diagnosis of stage 4 disease and before start of nivolumab. Albumin levels were measured before starting nivolumab. BMI, SMI, FFMI, and FMI were evaluated from CT scans performed at start of nivolumab. Overall survival (OS) was from starting of nivolumab to death or censured at last follow-up. Statistical analysis was done to identify correlation between the various factors and between those factors and survival. Forty-six patients with advanced non-small cell lung cancer (NSCLC) were included. Median follow-up was 22 months. Pathology was Adenocarcinoma/Squamous/non-other specified in 25/15/6 respectively. All patients received nivolumab as an advanced-line treatment for stage IV NSCLC. We observed a significant correlation of weight loss ( Weight loss and low albumin levels are significant negative prognostic factors for NSCLC patients on immunotherapy. CT-based parameters of body composition remain to be proven as more reliable than standard clinical parameters.
Identifiants
pubmed: 31564979
doi: 10.2147/CMAR.S210958
pii: 210958
pmc: PMC6733251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8201-8207Informations de copyright
© 2019 Magri et al.
Déclaration de conflit d'intérêts
DU reports personal fees from Bristol Myers Squibb and Roche outside the submitted work. JB reports grants, serves on advisory board, received honoraria from MSD, other BMS, Roche, AstraZeneca, Pfizer, Abbvie, Takeda, and VBL outside the submitted work. DO reports personal fees from BMS, MSD, BI and AstraZeneca, outside the submitted work. All other authors report no conflicts of interest in this work.
Références
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Lung Cancer. 2016 Nov;101:92-97
pubmed: 27794415
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Oncol. 2010 Aug;21(8):1594-8
pubmed: 20089558
Invest New Drugs. 2017 Aug;35(4):436-441
pubmed: 28396974
Eur J Cancer. 1996 Jun;32A(7):1135-41
pubmed: 8758243
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cell Metab. 2012 Aug 8;16(2):153-66
pubmed: 22795476
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Sci Rep. 2019 Feb 21;9(1):2447
pubmed: 30792455
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Thorac Oncol. 2015 Dec;10(12):1795-9
pubmed: 26484630
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Cancer Immunol Res. 2018 Jan;6(1):79-86
pubmed: 29208646
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Ann Surg Oncol. 2015 Dec;22(13):4432-7
pubmed: 25862583
Br J Cancer. 2002 Jul 29;87(3):264-7
pubmed: 12177792